Business Context and Reporting Period
This Form 8-K, dated November 22, 2023, reports material corporate governance changes and a corporate name change for Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.). The filing details the appointment of a new Chief Executive Officer, changes to the Board of Directors, and the official rebranding of the company effective November 28, 2023.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, or debt levels. The only financial figures disclosed relate to executive compensation and equity grants:
- CEO Base Salary: $625,000 annually.
- CEO Target Bonus: 55% of base salary.
- CEO Equity Grant: Option to purchase 374,000 shares at an exercise price of $10.39 per share.
- Director Equity Grants: Options to purchase 50,000 shares each for new directors Laurie Stelzer and Jeffrey Albers.
Material Changes Versus Prior Period
The filing outlines significant structural and leadership shifts:
- Corporate Name and Symbol: The company changed its name from "Aeglea BioTherapeutics, Inc." to "Spyre Therapeutics, Inc." and its trading symbol from "AEGL" to "SYRE" on the Nasdaq Capital Market, effective November 28, 2023.
- Executive Leadership: Cameron Turtle, DPhil, was appointed Chief Executive Officer, effective November 22, 2023, succeeding his role as Chief Operating Officer.
- Board Composition:
- Resignations: Ivana Magovčević-Liebisch, Ph.D., J.D. and Hunter C. Smith, M.B.A. resigned from the Board.
- Appointments: Cameron Turtle (Class I), Laurie Stelzer (Class I), and Jeffrey Albers (Class II) were appointed to the Board.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, forward-looking projections, or a discussion of specific business risks. Management commentary is limited to the biographies of the new leadership and the rationale for the name change. The resignations of the former directors were explicitly stated to be unrelated to any disagreements regarding the company's operations, policies, or practices.
Key Facts for Investor Verification
- Verify the new trading symbol "SYRE" on the Nasdaq Capital Market effective November 28, 2023.
- Review the amended and restated letter agreement (Exhibit 10.1) for full details on CEO severance terms, including 12 months of base salary for involuntary termination and 18 months plus full equity acceleration in the event of a change in control.
- Confirm the new Board composition and committee assignments, specifically Laurie Stelzer as Chair of the Audit Committee.
- Note that existing stock certificates reflecting the former name remain valid until exchanged.